With the acceleration of Chikungunya outbreaks being reported in Europe during the spring of 2025, older Europeans now have two approved vaccines to choose from before visiting an at-risk area this summer.
As of July 11, 2025, Valneva SE announced that the European Medicines Agency (EMA) will lift the temporary restriction on vaccinating people aged 65 years and above after concluding a thorough review of Valneva's single-dose Chikungunya vaccine IXCHIQ® by the EMA's safety committee.
Older Europeans Have Two Chikungunya Vaccine Options
Risk for Severe COVID-19 Elevated for Childhood Cancer Survivors
However, childhood cancer survivors have lower risk for registered COVID-19 infection relative to comparators
FDA Fully Approves Moderna’s COVID Vaccine for Some Young Kids
By I. Edwards HealthDay ReporterFRIDAY, July 11, 2025 (HealthDay News) — Moderna’s COVID-19 vaccine has received full approval from the U.S. Food and Drug Administration (FDA) for use in children …